5 active not recruiting, 4 completed, 4 recruiting, 3 terminated. 8 Phase 2, 7 Phase 1, 2 Not applicable, 2 Phase 3.
Follow Non-small Cell Carcinoma: new trials by email Literature Review of Non-small Cell Carcinoma trials Research Report on Non-small Cell Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC) PF-08046054, Docetaxel monotherapy - Non-small Cell Carcinoma, Non-Small Cell Lung Cancer Metastatic | Phase 3 | Recruiting | Pfizer | 680 | 2025-09-29 | 2026-10-13 |
| A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors TSC-204-A0201, TSC-204-C0702, TSC-200-A0201 - Head and Neck Cancer, Cervical Cancer | Phase 1 | Active not recruiting | TScan Therapeutics, Inc. | 840 | 2024-05-06 | 2025-11-17 |
| Physical Activity Coaching After Surgery for Patients With Resectable Non-small Cell Lung Cancer Physical activity tele coaching program - Non Small Cell Lung Cancer, Non-small Cell Carcinoma | Not applicable | Recruiting | University Hospital, Ghent | 90 | 2024-01-01 | 2025-11-18 |
| Combining ICI With SBRT or HypoFrx-RT for ES NSCLC Stereotactic body radiotherapy, Hypofractionated radiotherapy, Durvalumab - Non-small Cell Lung Cancer, Non-small Cell Carcinoma | Phase 1 / Phase 2 | Unknown | Alexander Chi | 83 | 2023-10-09 | 2023-10-03 |
| A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors vobramitamab duocarmazine 2.0 mg (Arm A), vobramitamab duocarmazine 2.7 mg (Arm B), vobramitamab duocarmazine - Castration-Resistant Prostatic Cancer, Androgen-Independent Prostatic Cancer | Phase 2 | Terminated | MacroGenics | 192 | 2023-06-13 | 2026-02-09 |
| Study to Determine the Safety and Pharmacokinetics of DO-2 in Patients With Advanced or Refractory Solid Tumours DO-2 - Adult Solid Tumor, Advanced Solid Tumor | Phase 1 | Recruiting | DeuterOncology | 55 | 2022-12-20 | 2026-04-03 |
| A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC) L-SABR, Anti-PD-(L)1 based immunotherapy, Platinum based chemotherapy - Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 68 | 2022-12-09 | 2026-05-07 |
| Investigating the Feasibility of a Physical Activity (tele)coaching Intervention in Patients with Non-small Cell Lung Cancer: an Explorative Study Automated Coaching Program (ACP), Manual Coaching Program (MCP) - Non-small Cell Lung Cancer, Non-small Cell Carcinoma | Not applicable | Completed | Hasselt University | 19 | 2022-10-01 | 2024-10-04 |
| Observational Study of the Efficacy and Safety of Anlotinib Combined With Penpulimab in Elderly Lung Cancer Patients Anlotinib and Penpulimab - Lung Cancer, Lung Carcinoma | Unknown | The First Affiliated Hospital of Xinxiang Medical College | 40 | 2022-05-16 | 2022-05-20 | |
| Ramucirumab, Atezolizumab and N-803 After Progression on Any Immune Checkpoint Blocker in NSCLC Ramucirumab, Atezolizumab, N-803 - Non-small Cell Lung Cancer, Non-small Cell Carcinoma | Phase 2 | Withdrawn | Washington University School of Medicine | 2021-10-31 | 2021-11-05 | |
| Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung Cancer Zimberelimab, Domvanalimab, Etrumadenant - Non Small Cell Lung Cancer, Non-small Cell Carcinoma | Phase 2 | Active not recruiting | Washington University School of Medicine | 30 | 2021-08-04 | 2026-06-08 |
| Osimertinib Monotherapy or Combination With Chemotherapy for Advanced NSCLC Concurrent EGFR and TP53 Mutations Osimertinib, Pemetrexed, Carboplatin - Non-small Cell Carcinoma, EGFR Gene Mutation | Phase 3 | Active not recruiting | Li Zhang, MD | 294 | 2021-03-29 | 2025-10-15 |
| Nodify XL2 Classifier Clinical Utility Study in Low to Moderate Risk Lung Nodules Nodule Solitary Pulmonary, Non-small Cell Carcinoma | Active not recruiting | Biodesix, Inc. | 2000 | 2020-12-18 | 2025-09-19 | |
| Durvalumab Followed by Chemoradiation and Consolidation Durvalumab for Stage III Non-small Cell Lung Cancer Induction Durvalumab, Chemotherapy, Radiation - Lung Cancer, Non-small Cell Carcinoma | Phase 2 | Terminated | Rachel Sanborn | 10 | 2020-06-18 | 2024-12-20 |
| Study of Binimetinib in Combination With Pembrolizumab in Advanced Non-Small Cell Lung Cancer Binimetinib, Pembrolizumab - Non-small Cell Carcinoma | Phase 1 | Active not recruiting | University Health Network, Toronto | 40 | 2019-09-20 | 2026-06-23 |
| A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer RGX-104, Ipilimumab, Docetaxel - Endometrial Cancer, Endometrial Cancer Recurrent | Phase 1 | Completed | Inspirna, Inc. | 146 | 2016-11-01 | 2025-03-26 |
| Intrapleural Docetaxel Administration Using Medical Pleuroscopy in Malignant Effusion With Lung Cancer intrapleural docetaxel administration - Pleural Effusion, Malignant, Non-small Cell Carcinoma | Phase 2 | Completed | Asan Medical Center | 4 | 2016-07-26 | 2019-03-08 |
| Safety Study of SEA-CD40 in Cancer Patients Intravenous (IV) SEA-CD40, Pembrolizumab, Subcutaneous (SC) SEA-CD40 - Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell | Phase 1 | Terminated | Seagen Inc. | 159 | 2015-02-28 | 2023-05-01 |
| Vaccine Treatment for Advanced Non-Small Cell Lung Cancer Drug: Hyperacute Lung Cancer Cell Vaccine - Non-small Cell Carcinoma, Adenocarcinoma of Lung | Phase 1 / Phase 2 | Completed | NewLink Genetics Corporation | 54 | 2003-11-01 | 2020-05-28 |
Carcinoma, Non-Small-Cell Lung (13) · Lung Neoplasms (5) · Melanoma (3) · Neoplasms (3) · Carcinoma, Squamous Cell (2) · Head and Neck Neoplasms (2) · Small Cell Lung Carcinoma (2) · Squamous Cell Carcinoma of Head and Neck (2) · Adenocarcinoma of Lung (1) · Anus Neoplasms (1) · Carcinoma, Large Cell (1) · Carcinoma, Small Cell (1) · Endometrial Neoplasms (1) · Hodgkin Disease (1) · Lymphoma (1)
Neoplasms by Site (16) · Respiratory Tract Diseases (16) · Lung Diseases (15) · Respiratory Tract Neoplasms (15) · Thoracic Neoplasms (15) · Bronchial Neoplasms (13) · Carcinoma, Bronchogenic (13) · Neoplasms (13) · Lung Neoplasms (9) · Neoplasms by Histologic Type (4) · Carcinoma (3) · Genital Diseases (3) · Neoplasms, Germ Cell and Embryonal (3) · Neoplasms, Glandular and Epithelial (3) · Neoplasms, Nerve Tissue (3)
Carboplatin (3) · Pemetrexed (3) · pembrolizumab (3) · durvalumab (2) · 130-nm albumin-bound paclitaxel (1) · ALT-803 (1) · Albumin-Bound Paclitaxel (1) · Cisplatin (1) · Docetaxel (1) · Drug Therapy (1) · Etoposide (1) · Gemcitabine (1) · Injections, Subcutaneous (1) · Ipilimumab (1) · Platinum Compounds (1)
Washington University School of Medicine (2) · Alexander Chi (1) · Asan Medical Center (1) · Biodesix, Inc. (1) · DeuterOncology (1) · Hasselt University (1) · Inspirna, Inc. (1) · Li Zhang, MD (1) · MacroGenics (1) · Memorial Sloan Kettering Cancer Center (1) · NewLink Genetics Corporation (1) · Pfizer (1) · Rachel Sanborn (1) · Seagen Inc. (1) · TScan Therapeutics, Inc. (1)
United States (10) · Belgium (5) · China (4) · Canada (3) · France (3) · South Korea (3) · Australia (2) · Italy (2) · Netherlands (2) · Poland (2) · Spain (2) · United Kingdom (2) · Argentina (1) · Brazil (1) · Bulgaria (1)
Daniel Morgensztern, M.D. (2) · Alexander Chi, MD (1) · Arun Rajan, M.D. (1) · Chris Burtin, PhD (1) · Dawn Pinchasik, MD (1) · Dieter Stevens, MD (1) · Gerard Silvestri, MD (1) · Heleen Demeyer, PhD (1) · Jaap Verweij, MD (1) · Liudmila Schafer, M.D. (1) · Michael Schmitt, MD, PhD (1) · Natasha Leighl, M.D. (1) · Paul Romesser, MD (1)
PMID 37385724, PMID 40898159, PMID 42574006
2025 (1)